The Surprising Thermodynamics of Amantadine Hydrochloride
NIST chemists have published the first data on the thermodynamic properties of amantadine hydrochloride, used for many years as the active pharmaceutical ingredient for antiviral and anti-parkinsonian medications. The new information can help optimize production and storage conditions of this important compound. Its structure in the gas phase was obtained by quantum chemistry methods. In the molecular structure, C is carbon, H is hydrogen, N is nitrogen, and Cl is chlorine. Credit: Bazyleva/NIST
Amantadine hydrochloride may be the most common medication you’ve never heard of. This compound has been around for decades as the basis for antiviral and other medications, from flu therapy to treatments for brain disorders such as Parkinson's disease and the fatigue associated with multiple sclerosis.
And yet, this compound has long been a bit of an enigma because of missing information on its properties. Now, chemists at the National Institute of Standards and Technology (NIST) and collaborators have published the very first data (link is external) on this important chemical’s thermodynamic properties, including data on how it responds to heat and changes from a solid into a gas.
Such data are valuable to the chemical and pharmaceutical industries for getting the highest production yields and shelf life for the medication.
“Our research results are not directly related to the medical application of this multifunctional drug, although I am really fascinated by the range of its pharmacological activity,” NIST research chemist Ala Bazyleva said.
“We studied its thermodynamic properties and decomposition,” Bazyleva said. “It is surprising, given the long history of amantadine-based drugs, that there is almost no information like this in the literature for many of them. Chemical engineers often have to rely on estimates and predictions based on similar compounds. Collating this information and developing these types of recommendations is at the core of what our group at NIST does.”
Amantadine hydrochloride belongs to a diamondoid class, a family of compounds whose structure is based on a cage of carbon atoms similar to diamond. Amantadine has a single carbon cage with a nitrogen atom attached on one side. Nonmedical studies have focused on the solid form of amantadine hydrochloride because it was expected to form disordered, or plastic, crystals, as many diamondoids do. Turns out, amantadine hydrochloride does not.
Bazyleva began studying amantadine hydrochloride years ago while in Belarus working on her doctoral dissertation, and continued the effort during her postdoctoral studies in Germany and Canada. But progress was slow, partly because adamantine hydrochloride changes from a solid directly into a gas (a process called sublimation) and simultaneously falls apart, or decomposes. She needed a model explaining this complex process, one that incorporates detailed, high-level calculations of quantum chemistry. She finally got access to this computational capability after she began working with the Thermodynamics Research Center (TRC) Group at NIST in Boulder several years ago.
“NIST was fundamental in facilitating the modeling component,” Bazyleva said. “In particular, the unique combination of facilities, software and expertise in quantum chemical computations allowed us to apply high-level calculations to get insight into the structure and stability of the drug in the gas phase.”
While the compound behaves like it is ionic (composed of positively and negatively charged pieces, though neutral overall) in the solid crystal form and when dissolved in a liquid, quantum chemistry calculations revealed that it decomposes into two neutral compounds in the gas phase.
Bazyleva, A., Blokhin, A., Zaitsau, D., Kabo, G., Paulechka, E., Kazakov, A. and Shaw, J. (2017). Thermodynamics of the Antiviral and Antiparkinsonian Drug Amantadine Hydrochloride: Condensed State Properties and Decomposition. Journal of Chemical & Engineering Data.
This article has been republished from materials provided by NIST. Note: material may have been edited for length and content. For further information, please contact the cited source.
CRISPR Reveals New Targets for Promising Cancer DrugsNews
Novel screening method identifies new drug targets that could potentially enhance the effectiveness of PD-1 checkpoint inhibitors, a promising new class of cancer immunotherapy.READ MORE
BioAscent Announces New CEO and Plans to Expand Discovery Services OfferingNews
BioAscent Discovery Limited appoints new CEO, Paul Smith in preparation for the expansion of companies discovery services.READ MORE
Cell Recycling System Offers Therapeutic Entry Point for Rare Disease TreatmentNews
Scientists have demonstrated how an investigational drug works against a rare, fatal genetic disease, Niemann-Pick type C1 (NPC1).READ MORE
Comments | 0 ADD COMMENT
EMBL Conference: European Conference of Life Science Funders and Foundations
Apr 19 - Apr 20, 2018
EMBL Course: Target Engagement in Biology and Drug Discovery
Feb 19 - Feb 23, 2018